Equities

Chengdu Easton Biopharmaceuticals Co Ltd

688513:SHH

Chengdu Easton Biopharmaceuticals Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)32.69
  • Today's Change0.16 / 0.49%
  • Shares traded409.87k
  • 1 Year change-6.14%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,5091,3391,490
Total Receivables, Net182192149
Total Inventory161141104
Prepaid expenses132921
Other current assets, total178.4015
Total current assets1,8831,7091,779
Property, plant & equipment, net1,2821,170921
Goodwill, net------
Intangibles, net847742
Long term investments81492.53
Note receivable - long term------
Other long term assets2.53--14
Total assets3,3473,0182,775
LIABILITIES
Accounts payable135148158
Accrued expenses637257
Notes payable/short-term debt22711770
Current portion long-term debt/capital leases2.93----
Other current liabilities, total232193147
Total current liabilities661529432
Total long term debt4000
Total debt27011770
Deferred income tax1.460.880.12
Minority interest------
Other liabilities, total414351
Total liabilities743573484
SHAREHOLDERS EQUITY
Common stock120120120
Additional paid-in capital1,4441,4441,444
Retained earnings (accumulated deficit)1,041880728
Treasury stock - common(1.59)----
Unrealized gain (loss)------
Other equity, total------
Total equity2,6032,4442,292
Total liabilities & shareholders' equity3,3473,0182,775
Total common shares outstanding176177177
Treasury shares - common primary issue0.0400
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.